Topical treatment with SPHINGOLIPIDS and GLYCOSAMINOGLYCANS for canine atopic dermatitis
Open Access
- 20 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Veterinary Research
- Vol. 16 (1), 1-10
- https://doi.org/10.1186/s12917-020-02306-6
Abstract
Background Skin barrier dysfunction plays a key role in atopic dermatitis (AD). This impairment is related to altered composition and metabolism of epidermal sphingolipids and a deficiency of ceramides. Glycosaminoglycans (GAGs), and especially hyaluronic acid, could be useful in the management of AD. This study aimed to evaluate the effects of a novel topical treatment consisting of sphingolipids and GAGs extracts in dogs with AD. This formulation is different from previously tested products because the sphingolipid extract contained high amounts of sphingomyelin, a precursor of ceramides, and this has been shown to enhance endogenous synthesis of ceramides and to increase lamellar-related structures in vitro. Thus, it was hypothesized that this formulation could improve clinical disease and skin barrier function in patients with AD. Results Twelve house dust mite (HDM) allergic atopic beagle dogs were randomized into two groups: control (n = 6; no treatment) or treatment (n = 6; topical sphingolipids and GAGs twice weekly for 8 weeks). Dogs were challenged with allergen twice weekly and the severity of dermatitis was scored using the canine atopic dermatitis and extent severity index (CADESI-03) once weekly. Skin barrier function (measurement of transepidermal water loss) and severity of pruritus (both pruritus visual analog scale [PVAS] and pruritus timed episodes) were assessed at 0, 4 and 8 weeks of treatment. Assessments were done by personnel unaware of group allocation. Complete blood count, serum biochemistry and stratum corneum (SC) lipidomics analyses were done at baseline and at week 8. Compared to baseline, significant increases in CADESI (P = 0.0003) and PVAS (P = 0.041) were observed only in the control group, and SC polyunsaturated fatty acids increased significantly only with treatment (P = 0.039). Compared to control, treatment group had a significantly lower CADESI after 1 week (P = 0.0078) and a significantly lower PVAS after 8 weeks (P = 0.0448). Treatment was well tolerated. Conclusions In this study in dogs with AD, a new topical formulation containing sphingomyelin-rich sphingolipids plus GAGs extracts attenuated the clinical worsening induced by HDM, supporting its use in atopic patients, either as an adjunctive treatment or used as monotherapy in certain cases.Keywords
This publication has 53 references indexed in Scilit:
- Evidence‐based guidelines for anti‐allergic drug withdrawal times before allergen‐specific intradermal and IgE serological tests in dogsVeterinary Dermatology, 2013
- Clinical use of a ceramide-based moisturizer for treating dogs with atopic dermatitisJournal of Veterinary Science, 2013
- Treating atopic dermatitis: safety, efficacy, and patient acceptability of a ceramide hyaluronic acid emollient foamClinical, Cosmetic and Investigational Dermatology, 2012
- A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitisJournal of Cosmetic Dermatology, 2011
- Spot-On Skin Lipid Complex as an Adjunct Therapy in Dogs with Atopic Dermatitis: An Open Pilot StudyVeterinary Medicine International, 2011
- Evaluation of a hand-held evaporimeter (VapoMeter®) for the measurement of transepidermal water loss in healthy dogsVeterinary Dermatology, 2010
- Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanismsJournal of Allergy and Clinical Immunology, 2008
- Development of an owner‐assessed scale to measure the severity of pruritus in dogsVeterinary Dermatology, 2007
- Revised nomenclature for veterinary allergyVeterinary Immunology and Immunopathology, 2006
- The ACVD task force on canine atopic dermatitis (XXIII): are essential fatty acids effective?Veterinary Immunology and Immunopathology, 2001